Skip to content
Licensed Unlicensed Requires Authentication Published by De Gruyter April 16, 2014

Clinical features at diagnosis and responses to antithyroid drugs in younger children with Graves’ disease compared with adolescent patients

  • Hirokazu Sato EMAIL logo , Kanshi Minamitani , Masanori Minagawa , Itsuro Kazukawa , Shigetaka Sugihara , Kunio Wataki , Susumu Konda , Hiroaki Inomata , Kazunori Sanayama , Yoichi Kohno and Nozomu Sasaki

Abstract

Objective: The aim of this study was to evaluate clinical manifestations, laboratory findings, and effects of antithyroid drugs in younger children with Graves’ disease (GD).

Design: A retrospective and collaborative study.

Setting: Nine facilities in Chiba prefecture, Japan.

Patients: We analyzed 132 children and adolescents with GD. The subjects were divided according to the median age into a group of young children (group I, 4.1–12.4 years, n=66) and an adolescent group (group II, 12.5–15.9 years, n=66).

Main outcome measures: Clinical manifestations, laboratory findings, incidence of adverse effects, and remission rates 5 years after initial therapy were assessed.

Results: The mean height SD score of group I (1.0) was higher than that of group II (0.3, p<0.001). The mean BMI SD score of group I (–0.7) was lower than that of group II (–0.3, p<0.05). The most common presentations were goiter, sweating, and hyperactivity in group I, whereas the most common presentations were goiter, sweating, and easy fatigability in group II. Hyperactivity was more frequent in group I (56.7%) than in group II (37.9%, p<0.05). Liver dysfunction appeared more often in group I (14.3%) than in group II (1.9%, p<0.05). There was no difference in the appearance of adverse effects between the two groups. The remission rate was slightly lower in group I (23.1%) than in group II (31.3%), but was not significant.

Conclusions: Thyrotoxicosis had more influence on the growth and liver function in younger children.


Corresponding author: Hirokazu Sato MD, Sunrise Children’s Clinic, Nakayama Medical Square 1F, 4-22-10 Motonakayama, Funabashi, Chiba 273-0035, Japan, Phone: +81-47-333-8222, Fax: +81-47-333-2733, E-mail:
aH. Sato performed the statistical analysis and wrote the first draft of the manuscript, and the other authors are collaborating researchers.

Acknowledgments

We are indebted to the honorary professor of Chiba University, Hironori Nakajima, for finding our group for clinical research on pediatric endocrinology; the honorary professor of Chiba University, Hiroo Niimi, for subsequent development of the group; Dr. Toshiaki Tsuyusaki and Dr. Kiyoe Tamaru for their investigation of Graves’ disease in the group; and all physicians in each facility for their cooperation with the study.

Conflict of interest statement: The authors have no conflict of interest to declare.

References

1. Shulman DI, Muhar I, Jorgensen EV, Diamond FB, Bercu BB, et al. Autoimmune hyperthyroidism in prepubertal children and adolescents: comparison of clinical and biochemical features at diagnosis and responses to medical therapy. Thyroid 1997;7:755–60.10.1089/thy.1997.7.755Search in Google Scholar PubMed

2. Lazar L, Kalter-Leibovici O, Pertzelan A, Weintrob N, Josefsberg Z, et al. Thyrotoxicosis in prepubertal children compared with pubertal and postpubertal patients. J Clin Endocrinol Metab 2000;85:3678–82.10.1210/jcem.85.10.6922Search in Google Scholar PubMed

3. Hung CS, Chang LY, Sui HH, Chao T, Van YH, et al. Clinical and laboratory findings at initial diagnosis in pediatric Graves’ disease in Taiwan. Acta Paeditr Taiwan 2006;47:77–82.Search in Google Scholar

4. Poyrazoglu S, Saka N, Bas F, Isguven P, Dogu A, et al. Evaluation of diagnosis and treatment results in children with Graves’ disease with emphasis on the pubertal status of patients. J Pediatr Endocrinol Metab 2008;21:745–51.10.1515/JPEM.2008.21.8.745Search in Google Scholar PubMed

5. Kaguelidou F, Albeti C, Castanet M, Guitteny MA, Czernichow P, et al.; the French Childhood Graves’ Disease Study Group. Predictors of autoimmune hyperthyroidism relapse in children after discontinuation of antithyroid drug treatment. J Clin Endocrinol Metab 2008;93:3817–26.10.1210/jc.2008-0842Search in Google Scholar PubMed

6. Glaser NS, Styne DM, Organization of Pediatric Endocrinologists of Northern California Collaborative Graves’ Disease Study Group. Predicting the likelihood of remission in children with Graves’ disease: a prospective, multicenter study. Pediatrics 2008;121:e481–8.10.1542/peds.2007-1535Search in Google Scholar PubMed

7. Sato H, Harada S, Yokoya S, Tanaka T, Asayama K, et al. Treatment for childhood-onset Graves’ disease in Japan: results of nationwide questionnaire survey of pediatric endocrinologists and thyroidologists. Thyroid 2007;17:67–72.10.1089/thy.2006.0193Search in Google Scholar PubMed

8. Sato H, Sasaki N, Harada S, Tanaka T, Akasu F, et al. Guidelines for the treatment of childhood-onset Graves’ disease with antithyroid drug in Japan 2008. J Jap Pediatr Soc 2008;112:946–52 (in Japanese).Search in Google Scholar

9. Bahn RS, Burch HB, Cooper DS, Garber JR, Greenlee MC, et al. Hyperthyroidism and other causes of thyrotoxicosis: management guideline of the American Thyroid Association and American Association of Clinical Endocrinologists. Thyroid 2011;21:593–646.10.1089/thy.2010.0417Search in Google Scholar PubMed

10. Rivkees SA, Mattison DR. Ending propylthiouracil-induced liver failure in children. N Engl J Med 2009;350:1574–5.Search in Google Scholar

11. Rivkees SA, Szarfman A. Dissimilar hepatotoxicity profiles of propylthiouracil and methimazole in children. J Clin Endocrinol Metab 2010;95:3260–7.10.1210/jc.2009-2546Search in Google Scholar PubMed

12. Sato H, Hattori M, Fujieda M, Sugihara S, Inomata H, et al. High prevalence of antineutrophil cytoplasmic antibody positivity in childhood onset Graves’ disease treated with propylthiouracil. J Clin Endocrinol Metab 2000;85:4270–3.Search in Google Scholar

13. Fujieda M, Hattori M, Kurayama H, Koitabashi Y, and members and coworkers of the Japanese Society for Pediatric Nephrology. Clinical features and outcomes in children with antineutrophil cytoplasmic autoantibody–positive glomerulonephritis associated with propylthiouracil treatment. J Am Soc Nephrol 2002;13:437–45.10.1681/ASN.V132437Search in Google Scholar PubMed

14. Yoshimura JN, Yasuda S, Sato S, Matsumoto M, Kunii Y, et al. Clinical characteristics of myeloperoxidase antineutrophil cytoplasmic antibody-associated vasculitis caused by antithyroid drugs. J Clin Endocrinol Metab 2009;94:2806–11.10.1210/jc.2008-2700Search in Google Scholar PubMed

15. Sato H, Minagawa M, Sasaki N, Sugihara S, Kazukawa I, et al. Comparison of methimazole and propylthiouracil in the management of children and adolescents with Graves’ disease: efficacy and adverse reactions during initial treatment and long-term outcome. J Pediatr Endocrinol Metab 2011;24:257–63.10.1515/jpem.2011.194Search in Google Scholar PubMed

16. The Japan Thyroid Association. Guideline for the diagnosis of Graves’ disease. Available at: http://www.japanthyroid.jp/doctor/guideline/english.html.Search in Google Scholar

17. Sato H, Sasaki N, Minamitani K, Minagawa M, Kazukawa I, et al. Higher dose of methimazole causes frequent adverse effects in the management of Graves’ disease in children and adolescents. J Pediatr Endocrinol Metab 2012;25:863–7.10.1515/jpem-2012-0138Search in Google Scholar PubMed

18. Ohyama K. Physiology of puberty. In: The Japanese Society for Pediatric Endocrinology, editor. Pediatric endocrinology. Tokyo: Shindan to Chiryosha, 2009:268–72.Search in Google Scholar

19. Cassio A, Corrias A, Gualandi S, Tato’ L, Cesaretti G, et al. Influence of gender and pubertal stage at diagnosis on growth outcome in childhood thyrotoxicosis: results of a collaborative study. Clin Endocrinol (Oxf) 2006;64:53–7.10.1111/j.1365-2265.2005.02415.xSearch in Google Scholar PubMed

20. Wong GW, Lai J, Cheng PS. Growth in childhood thyrotoxicosis. Eur J Pediatr 1999;158:776–9.10.1007/s004310051202Search in Google Scholar PubMed

21. Jaruratanasirikul S, Sriplung H. Growth pattern of childhood thyrotoxicosis: longitudinal follow-up to final height. 2006;89:1396–9.Search in Google Scholar

22. Bossowski AT, Reddy V, Perry LA, Johnston LB, Banerjee K, et al. Clinical and endocrine features and long-term outcome of Graves’ disease in early childhood. J Endocrinol Invest 2007;30:388–92.10.1007/BF03346315Search in Google Scholar PubMed

23. Manji N, Carr-Smith JD, Boelaert K, Allahabadia A, Armitage M, et al. Influences of age, gender, smoking, and family history on autoimmune thyroid disease phenotype. J Clin Endocrinol Metab 2006;91:4873–80.10.1210/jc.2006-1402Search in Google Scholar PubMed

24. Leger J, Gelwane G, Kaguelidou F, Benmerad M, Alberti C, and the French Childhood Graves’ Disease Study Group. Positive impact of long-term antithyroid drug treatment on the outcome of children with Graves’ disease: national long-term cohort study. J Clin Endocrinol Metab 2012;97:110–9.10.1210/jc.2011-1944Search in Google Scholar PubMed

25. Ohye H, Minagawa A, Yoshimura NJ, Mukasa K, Kunii Y, et al. Antithyroid drug treatment for Graves’ disease in children: a long-term retrospective study at a single institution. Thyroid 2014;24:200–7.10.1089/thy.2012.0612Search in Google Scholar PubMed

26. Sugino K, Ito K, Mimura T, Fukunari N, Nagahama M, et al. Surgical treatment of Graves’ disease in children. Thyroid 2004;14:447–52.10.1089/105072504323150769Search in Google Scholar PubMed

Received: 2013-7-7
Accepted: 2014-2-28
Published Online: 2014-4-16
Published in Print: 2014-7-1

©2014 by Walter de Gruyter Berlin/Boston

Downloaded on 28.3.2024 from https://www.degruyter.com/document/doi/10.1515/jpem-2013-0288/html
Scroll to top button